Table 1.
Clinical features of BRCA patients in the TCGA and meta-validation dataset.
| Clinical Features |
TCGA (n = 1083) |
GSE42568 (n = 104) |
GSE88770 (n = 117) |
|---|---|---|---|
|
OS Alive Dead |
933 (86.15%) 150 (13.85%) |
69 (66.35%) 35 (33.65%) |
89 (76.07%) 28 (23.93%) |
|
Age ≤58 >58 |
545 (50.32%) 538 (49.68%) |
56 (53.85%) 48 (46.15%) |
- - |
|
Grade G1 G2 G3 |
- - - |
11 (10.58%) 40 (38.46%) 53 (50.96%) |
13 (11.11%) 96 (82.05%) 7 (5.98%) |
|
PR status Positive Negative Indeterminate |
688 (63.53%) 342 (31.58%) 4 (0.37%) |
- - - |
79 (67.52%) 37 (31.62%) |
|
ER status Positive Negative Indeterminate |
795 (73.41%) 238 (21.98%) 2 (0.18%) |
- - - |
106 (90.60%) 11 (9.40%) - |
|
HER2 status Positive Negative Indeterminate |
161 (14.87%) 557 (51.43%) 12 (1.11%) |
- - - |
7 (5.98%) 108 (92.31%) - |
|
Stage Stage I Stage II Stage III Stage IV Stage X |
182 (16.81%) 613 (56.60%) 247 (22.81%) 19 (1.75%) 14 (1.29%) |
- - - - - |
- - - - - |
|
T stage T1 T2 T3 T4 |
279 (25.76%) 624 (57.62%) 138 (12.74%) 39 (3.60%) |
- - - - |
- - - - |
|
N stage N0 N1 N2 N3 |
512 (47.28%) 356 (32.87%) 119 (10.99%) 76 (7.02%) |
- - - - |
- - - - |
|
M stage M0 M1 |
901 (83.19%) 21 (1.94%) |
- - |
- - |
OS, overall survival; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.